Lilly wins further delay in sales of Strattera copies

Indianapolis-based Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, has won a court order extending
the ban on generic versions of the attention-deficit treatment Strattera while it appeals a patent ruling.

The U.S. Court of Appeals for the Federal Circuit Thursday said a temporary order imposed last week will continue to allow
the court to consider whether copies should be banned until the appeal is decided. The lower court order was set to expire
in two weeks.

The court, which specializes in patent law, also set a 35-day schedule for written arguments that would ensure the appeal
is heard quickly. Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic
competition would translate into an average $1.22 million in sales.

U.S. District Judge Dennis M. Cavanaugh this month invalidated a patent on the medicine, opening the door for generic copies
by as many as 10 companies, including Mylan Inc., Teva Pharmaceutical Industries Ltd. and Novartis AG’s Sandoz unit.

Generic-drug makers who had challenged the Strattera patent were Synthon BV; Iceland’s Actavis Group hf; Canada’s
Apotex Inc.; and India’s Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd. and
Cadila Healthcare Ltd.’s Zydus.
 

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.